CLLS

CellectisA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$5.35

+58.3% vs current

Most likely

Base case

60%

Probability

Target price

$4.01

+18.6% vs current

B-

Bear case

20%

Probability

Target price

$2.67

-21.0% vs current

AI sentiment snapshot

Latest data as of 2025-10-08

AI commentary

Market is cautious after Q3; focus remains on cash runway and UCART enrollment. Given low float and binary clinical catalysts, short-term headlines can move the stock. Overall neutral-to-slightly-negative absent clear de-risking.

RankAlpha Sentiment AI - 2025-10-08

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2025-10-07eventQ3 2025 results & program updateHigh impact

Q3 results (Oct 7, 2025) updating cash runway and UCART timelines; can prompt guidance revisions and near-term sentiment swings [#PRICE-API-2025-10-07][#PR-2025-10-07].

2026-03-31catalystFinancing / cash-runway announcementsHigh impact

Secondary financing or partnerships will either dilute equity or de-risk programs; terms will determine directional impact [#PR-2025-10-07].

2026-06-30eventClinical readouts / enrollment milestonesHigh impact

Positive early data or faster enrollment could re-rate the group; delays or safety signals would materially pressure valuation [#PR-2025-10-07][#OUR-PROGRAMS].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-10-08 • Updated nightlySource: Internal modelMethodology